Elritercept not checked
Takeda · TAK-226 · KER-050
FollowEvery change as it happens, and a Monday email
Trials
6 active
6 in total · 5 in the EU
Targets
—
None known yet
What this is
- How it works
- A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
- How it’s given
- “Elritercept (TAK-226, KER-050) administered subcutaneously every 4 weeks.”In the company’s words, NCT06499285 on ClinicalTrials.gov
- Tested for
- Myelodysplastic Syndromes (3 trials), Anemia (2 trials), Myelofibrosis (2 trials), Myelodysplastic Syndrome, Cytopenia
- Main trialPhase 3
- “The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.”In the company’s words, NCT06499285 on ClinicalTrials.gov
- Other names
- TAK-226 · KER-050
Other drugs for Myelodysplastic Syndromes
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- CrovalimabRoche · Phase 3
- DanicopanAlexion Pharmaceuticals, Inc. · Phase 3
- MomelotinibSierra Oncology LLC - a GSK company · Phase 2/3
- VenetoclaxAbbVie · Phase 3
Coming up6
- 28 Feb 2028Phase 2 trial completes · ClinicalTrials.gov
- 26 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- 15 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Apr 2029Phase 3 trial completes · ClinicalTrials.gov
- 30 Oct 2029Phase 2 trial completes · ClinicalTrials.gov
- 7 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 15 Sep 2028 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | |
| Phase 3Recruiting | 30 Apr 2029 | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions | |
| Phase 3Recruiting | 7 Dec 2029 | A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib | |
| Phase 2Recruiting | 28 Feb 2028 | A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis | |
| Phase 2Recruiting | 26 Jun 2028 | A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes | |
| Phase 2Recruiting | 30 Oct 2029 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026